Lyra Therapeutics Inc LYRA:NASDAQ

RT Quote | USD
Last | 04/18/24 EDT
5.39quote price arrow down-0.02 (-0.28%)
Volume
386,409
52 week range
1.93 - 6.79
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.41
  • 52 Week High6.79
  • 52 Week High Date03/27/24
  • 52 Week Low1.93
  • 52 Week Low Date04/24/23

Key Stats

  • Market Cap322.015M
  • Shares Out59.74M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.29
  • YTD % Change2.86

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.41
  • 52 Week High6.79
  • 52 Week High Date03/27/24
  • 52 Week Low1.93
  • 52 Week Low Date04/24/23
  • Market Cap322.015M
  • Shares Out59.74M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.29
  • YTD % Change2.86

RATIOS/PROFITABILITY

  • EPS (TTM)-1.32
  • P/E (TTM)-4.08
  • Fwd P/E (NTM)-4.94
  • EBITDA (TTM)-65.235M
  • ROE (TTM)-73.67%
  • Revenue (TTM)1.558M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-4,023.11%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lyra Therapeutics Inc

 

Profile

MORE
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are...
Harlan Waksal M.D.
Executive Chairman of the Board
Maria Palasis Ph.D.
President, Chief Executive Officer, Director
Jason Cavalier
Chief Financial Officer, Treasurer, Secretary
John Bishop Ph.D.
Chief Technology Officer
Address
480 Arsenal Way
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
OPT
Opthea Ltd
3.40UNCHUNCH
AVIR
Atea Pharmaceuticals Inc
3.70-0.01-0.27%
INZY
Inozyme Pharma Inc
4.58-0.07-1.51%
RAPT
RAPT Therapeutics Inc
7.93-0.11-1.37%
NAUT
Nautilus Biotechnology Inc
2.34-0.09-3.70%